2500 — Venus MedTech HangZhou Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 233 | 276 | 416 | 406 | 491 |
Cost of Revenue | |||||
Gross Profit | 195 | 227 | 324 | 314 | 389 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 593 | 458 | 780 | 1,504 | 1,152 |
Operating Profit | -360 | -182 | -364 | -1,098 | -660 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -382 | -186 | -378 | -1,156 | -735 |
Provision for Income Taxes | |||||
Net Income After Taxes | -381 | -183 | -371 | -1,122 | -729 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -381 | -182 | -374 | -1,058 | -704 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -381 | -182 | -374 | -1,058 | -704 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.17 | -0.444 | -0.497 | -1.76 | -1.24 |